Compensation available
Diagnosed with Major Depressive Disorder?
If you’re diagnosed with Major Depressive Disorder and are still searching for effective relief, especially if other treatments haven’t fully helped, consider a new path.
A new research trial is evaluating an investigational new treatment, offering a potential new option to explore for managing your symptoms.
SEE IF YOU QUALIFY
Fill out the personal health questions below to see if you meet the basic study requirements. Additional eligibility criteria apply. Your answers will be recorded, but your information will only be used for the purposes of this study to determine your eligibility.
WHY participate?
Contribute to advancing scientific research that could benefit others
Get the chance to take the investigational treatment, or a placebo, and potentially find relief
Receive compensation for your time and participation
WHAT'S involved?
- Fill out the form above
- We’ll call you to ask more questions
- If you qualify, attend a screening visit at the study site
- Attend 8 additional in-person visits at the study site
Frequently Asked Questions
The study medicine [SPT-300] is a new form of allopregnanolone attached to a fat-like molecule. Allopregnanolone is naturally made by the brain, where it works on brain receptors that help to regulate mood and stress. Allopregnanolone would be a new way to treat MDD. An injection of allopregnanolone was approved for use in a type of depression characterized by high anxiety and acute onset. However, that form of allopregnanolone is not well absorbed as a pill, meaning very little medicine gets into the body if taken as a pill. The study medicine [SPT-300] works differently to get allopregnanolone into the body. That allows allopregnanolone to be available as a once-daily oral pill.
This study medicine has been evaluated in humans previously and has a safety profile similar to other drugs being developed for MDD. It has been reviewed by a number of regulatory groups who have deemed it safe for study to proceed.
Participants will be assigned randomly (by chance, like flipping a coin) to receive either the study drug or placebo. Each participant will have a 1 in 2 (50%) chance of receiving the study drug and a 1 in 2 (50%) chance of receiving placebo.
Neither participants nor the study staff will know which treatment they are receiving. This is known as a “double-blinded” study. In case of an emergency, the study doctor will be able to find out which study treatment a participant is receiving at any time.
All participants, including those in the placebo group, will (if eligible) have the opportunity to receive the study drug by continuing in a 6-week extension to the trial.
There will be approximately 9 in-person visits to the study site.
Yes, a stipend will be provided to patients to support travel needs, such as Ubers, taxis, and buses.
Yes, compensation for your time and participation will be provided directly by the study site. Please note that exact compensation varies by site – please discuss this directly with the site coordinator to learn more.
Please note: 1nHealth may store your data in a confidential and secure database. That personal information will never be shared or sold with any other persons or organizations not associated with 1nHealth. 1nHealth may/will use personal information to contact you directly by phone and/or email for matters related to potential participation in clinical trials, studies, and projects for which the potential participant may qualify. See our Privacy Policy for more details.